Lateral internal sphincterotomy has been the standard treatment for chronic anal fissure, but fissure healing rates of up to 80% with topical glyceryl trinitrate (GTN) treatment have suggested that this operation may become redundant. We evaluated the results of topical treatment of chronic anal fissures with 0.2% GTN for 6 weeks in the outpatient clinical setting, outside the confines of a randomized clinical trial. The role of lateral internal sphincterotomy in the GTN era was also assessed.
INTRODUCTION
Lateral internal sphincterotomy (LIS) is a well-established treatment for chronic anal fissures and cure rates of over 95% have been reported1. However, the incidence of incontinence to faeces or flatus after this procedure ranges from 0% to 35%2. Recent controlled studies have raised interest in the nitric oxide donor glyceryl trinitrate (GTN), healing rates of up to 80% having been demonstrated after topical application for [6] [7] [8] weeks3'4. One commentator has even proposed that topical GTN may make surgical procedures for anal fissures obsolete5.
This study was undertaken to evaluate the efficacy of 0.2% GTN paste in the treatment of chronic anal fissure in the outpatient clinic setting, outside the confines of a clinical trial, and to determine whether LIS still has a role to play.
METHODS
All patients with chronic anal fissures (symptoms for 8 weeks or more) attending a single colorectal outpatient clinic over a 24-month period were included in the study. Patients were advised to apply 0.2% GTN paste topically to the anal verge twice daily for 6 weeks. Patient satisfaction with the treatment and fissure healing were assessed at 6 weeks. Patients with fissures that had not healed at 6 weeks went on to have a closed short LIS limited to the length of the fissure, performed under general anaesthesia as a day case procedure by a consultant colorectal surgeon or by a supervised higher surgical trainee. Patients were reassessed 6 weeks after LIS.
RESULTS
49 consecutive patients (28 men, 21 women) were studied. Their median age was 35 years (range 20-72). 6 patients had anterior fissures, 43 posterior.
Treatment outcome is summarized in Figure 1 . GTN induced fissure healing in 22 patients (45%): 21 (43%) required no further treatment, but 1 relapsed and subsequently underwent LIS. Spontaneous fissure healing was noted in 2 (4%) patients who discontinued GTN therapy after 2 weeks because of the onset of headache. LIS was performed in 26 (53%) patients who had persistent symptomatic fissures despite 6 weeks of GTN therapy. At the 6-week post-sphincterotomy review, all fissures had healed; all patients were satisfied with the operation and none complained of incontinence to faeces or flatus.
DISCUSSION
In controlled clinical trials topical GTN has cured 68-80% of chronic anal fissures3'4, whereas our cure rate with 0.2% GTN paste for 6 weeks was only 43%. There may be several reasons why GTN should be less effective outside the confines of a clinical trial. In controlled studies patients are reviewed more frequently than in the outpatient setting, and this close follow-up may improve patient compliance. One study included patients with acute as well as chronic fissures6, though most acute fissures resolve with simple measures such as dietary manipulation. The concentration of the GTN preparation (0.2%) used in this study was identical to that used in trials3'4'6, but the quantity of paste applied each time is somewhat arbitrary: patients were simply instructed to apply a 'thin film' to the anal verge, and our patients may have been more economical in their applications than their controlled trial counterparts. In addition, one group reported that 15 of their 19 patients required concentrations of GTN paste greater than 0.2% to achieve significant reductions in anal pressure: 8 of the 9 patients with healed fissures required a concentration of 0.3% GTN or greater7. In this study, as in the trials cited, twice daily dosage was chosen because of reports by Loder et al.8 that resting pressure remained reduced for up to 9 hours after topical application of 0.2% GTN. This prolonged action was demonstrated in only 2 patients, however. In a more recent study anal pressures had returned to pretreatment values in all 6 patients by 6 hours after application of topical 0.2% GTN9. More frequent dosage might give a more sustained reduction of anal pressure and better healing, though possibly with more side-effects.
Symptoms persisted in 53% of patients in this study after completion of GTN therapy. Treatment options at this stage included continued GTN therapy or LIS. Until recently LIS was the mainstay of treatment for chronic anal fissure. When the study was begun there were no clear guidelines on appropriate duration of therapy. It is noteworthy, however, that 9 patients who gained partial symptomatic relief were advised to continue GTN for 2-A weeks while awaiting sphincterotomy and none of these patients healed in this interval. We found that patients with troublesome symptoms despite 6 weeks of GTN were reluctant to persist with this treatment and opted for LIS when given the choice. Furthermore, the results of LIS were rewarding: there were no complications in the short term and patients were well satisfied.
The likelihood of recurrent fissures in the long term must also be considered. The primary pathology in most chronic anal fissures is hypertonicity of the internal anal sphincter, with subsequent compromise of the blood supply to the distal anal canal as branches of the inferior rectal arteries are compressed while traversing the sphincter. Consequently, what begins as a superficial mucosal tear, possibly as a result of stool trauma, becomes a non-healing ischaemic ulcer. Although topical GTN relaxes the internal sphincter, this so-called 'chemical sphincterotomy' is completely reversed on cessation of treatment and sphincter pressures return to pre-treatment values10. By contrast, after LIS, anal pressures remain normal for at least one year, probably much longer 1, and most recurrences appear within the first four postoperative monthsl2. The implication is that patients treated with GTN, although initially spared an operation, are more prone to recurrent fissures than those undergoing LIS.
It must be emphasized that GTN therapy is safe and only 2 (4%) patients in this study discontinued treatment because of headaches. Interestingly, the fissures healed spontaneously in both these patients. This safety, coupled with a fissure-healing rate of 43%, suggests that GTN should be used as first-line therapy for chronic anal fissures, LIS being reserved for fissures not responsive to GTN and recurrent fissures.
